Evaluation in STEMI Patients Using FDY-5301

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2351 participants.

Also called NCT04837001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,351 participants (enrolled count) (from the registry)
Sponsor
Faraday Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT04837001
  • EudraCT 2021-001924-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Hungary, Israel, Poland, Portugal (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04837001. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-02 (actual); primary completion 2025-09-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation in STEMI Patients Using FDY-5301
Acronym
IOCYTE AMI-3
Condition
Acute Myocardial Infarction
Condition
STEMI
Condition
Percutaneous Coronary Revascularization
Intervention (Drug)
FDY-5301
Intervention (Other)
Placebo
Lead sponsor
Faraday Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04837001
Content hash
f845f1184b9b14a8c3d8b0eceaaf60d1e3ae22793ca855b6317b2ce7ef238272